Literature DB >> 29750826

Conditional Deletion of Sost in MSC-Derived Lineages Identifies Specific Cell-Type Contributions to Bone Mass and B-Cell Development.

Cristal S Yee1,2, Jennifer O Manilay2, Jiun C Chang1,2, Nicholas R Hum1, Deepa K Murugesh1, Jamila Bajwa2, Melanie E Mendez1,2, Aris E Economides3, Daniel J Horan4, Alexander G Robling4, Gabriela G Loots1,2.   

Abstract

Sclerostin (Sost) is a negative regulator of bone formation and blocking its function via antibodies has shown great therapeutic promise by increasing both bone mass in humans and animal models. Sclerostin deletion in Sost KO mice (Sost-/- ) causes high bone mass (HBM) similar to sclerosteosis patients. Sost-/- mice have been shown to display an up to 300% increase in bone volume/total volume (BV/TV), relative to age-matched controls. It has been postulated that the main source of skeletal sclerostin is the osteocyte. To understand the cell-type specific contributions to the HBM phenotype described in Sost-/- mice, as well as to address the endocrine and paracrine mode of action of sclerostin, we examined the skeletal phenotypes of conditional Sost loss-of-function (SostiCOIN/iCOIN ) mice with specific deletions in (1) the limb mesenchyme (Prx1-Cre; targets osteoprogenitors and their progeny); (2) midstage osteoblasts and their progenitors (Col1-Cre); (3) mature osteocytes (Dmp1-Cre); and (4) hypertrophic chondrocytes and their progenitors (ColX-Cre). All conditional alleles resulted in significant increases in bone mass in trabecular bone in both the femur and lumbar vertebrae, but only Prx1-Cre deletion fully recapitulated the amplitude of the HBM phenotype in the appendicular skeleton and the B-cell defect described in the global KO. Despite WT expression of Sost in the axial skeleton of Prx1-Cre deleted mice, these mice also had a significant increase in bone mass in the vertebrae, but the sclerostin released in circulation by the axial skeleton did not affect bone parameters in the appendicular skeleton. Also, both Col1 and Dmp1 deletion resulted in a similar 80% significant increase in trabecular bone mass, but only Col1 and Prx1 deletion resulted in a significant increase in cortical thickness. We conclude that several cell types within the Prx1-osteoprogenitor-derived lineages contribute significant amounts of sclerostin protein to the paracrine pool of Sost in bone.
© 2018 The Authors. Journal of Bone and Mineral Research Published by Wiley Periodicals, Inc. © 2018 The Authors. Journal of Bone and Mineral Research Published by Wiley Periodicals, Inc.

Entities:  

Keywords:  CHONDROCYTE; MSC; OSTEOBLAST; OSTEOCYTE; SCLEROSTIN; WnT; WnT SIGNALING

Mesh:

Substances:

Year:  2018        PMID: 29750826     DOI: 10.1002/jbmr.3467

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  15 in total

Review 1.  Wnt Antagonists in Hematopoietic and Immune Cell Fate: Implications for Osteoporosis Therapies.

Authors:  Betsabel Chicana; Cristine Donham; Alberto J Millan; Jennifer O Manilay
Journal:  Curr Osteoporos Rep       Date:  2019-04       Impact factor: 5.096

Review 2.  The role of osteoblasts in energy homeostasis.

Authors:  Naomi Dirckx; Megan C Moorer; Thomas L Clemens; Ryan C Riddle
Journal:  Nat Rev Endocrinol       Date:  2019-08-28       Impact factor: 43.330

Review 3.  Sclerostin: from bench to bedside.

Authors:  Sakae Tanaka; Toshio Matsumoto
Journal:  J Bone Miner Metab       Date:  2020-11-18       Impact factor: 2.626

4.  Loss of BMP signaling mediated by BMPR1A in osteoblasts leads to differential bone phenotypes in mice depending on anatomical location of the bones.

Authors:  Honghao Zhang; Yanshuai Zhang; Masahiko Terajima; Genevieve Romanowicz; Yangjia Liu; Maiko Omi; Erin Bigelow; Danese M Joiner; Erik I Waldorff; Peizhi Zhu; Mekhala Raghavan; Michelle Lynch; Nobuhiro Kamiya; Rongqing Zhang; Karl J Jepsen; Steve Goldstein; Michael D Morris; Mitsuo Yamauchi; David H Kohn; Yuji Mishina
Journal:  Bone       Date:  2020-05-01       Impact factor: 4.398

5.  PPARG in osteocytes controls sclerostin expression, bone mass, marrow adiposity and mediates TZD-induced bone loss.

Authors:  Sudipta Baroi; Piotr J Czernik; Amit Chougule; Patrick R Griffin; Beata Lecka-Czernik
Journal:  Bone       Date:  2021-03-16       Impact factor: 4.626

6.  Cytoprotective Effect of Taurine against Hydrogen Peroxide-Induced Oxidative Stress in UMR-106 Cells through the Wnt/β-Catenin Signaling Pathway.

Authors:  Jing Lou; Donghe Han; Huihui Yu; Guang Yu; Meihua Jin; Sung-Jin Kim
Journal:  Biomol Ther (Seoul)       Date:  2018-11-01       Impact factor: 4.634

Review 7.  Sclerostin and Osteocalcin: Candidate Bone-Produced Hormones.

Authors:  Jialiang S Wang; Courtney M Mazur; Marc N Wein
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-10       Impact factor: 5.555

8.  Activation of creER recombinase in the mouse calvaria induces local recombination without effects on distant skeletal segments.

Authors:  Jue Hou; Charles P Lin; Giuseppe Intini
Journal:  Sci Rep       Date:  2021-04-15       Impact factor: 4.379

Review 9.  The Roles of Sclerostin in Immune System and the Applications of Aptamers in Immune-Related Research.

Authors:  Meiheng Sun; Zihao Chen; Xiaoqiu Wu; Yuanyuan Yu; Luyao Wang; Aiping Lu; Ge Zhang; Fangfei Li
Journal:  Front Immunol       Date:  2021-02-25       Impact factor: 7.561

Review 10.  Enlightenment of Growth Plate Regeneration Based on Cartilage Repair Theory: A Review.

Authors:  Xianggang Wang; Zuhao Li; Chenyu Wang; Haotian Bai; Zhonghan Wang; Yuzhe Liu; Yirui Bao; Ming Ren; He Liu; Jincheng Wang
Journal:  Front Bioeng Biotechnol       Date:  2021-06-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.